Skip to content
Noricum

R&D

Born in a laboratory, not in a catalogue.

Noricum is a spin-off of the Tissue Engineering and Bone Regeneration Group at the Complutense University of Madrid. Research is not a department here: it is where the company came from.

Noricum was born as a result of the research activity of the Tissue Engineering and Bone Regeneration Group at the Complutense University of Madrid. Since its foundation in September 2004, its research lines have adapted to the needs of each moment, with one constant goal: bringing bone morphogenetic proteins to real clinical application.

The work began with the protein. Developing in-house protocols for the cloning, expression, folding and purification of BMPs made it possible to obtain active dimeric protein at high yields. The advantage of those protocols is not only the yield: no organic solvents or detergents are used in the folding process, which lowers the cost and makes further experimentation viable.

Then came the carrier. A protein on its own is of no use if it does not reach where it has to reach: a biomaterial capable of releasing it in vivo was needed. The result was a film with a high capacity for cell adhesion that retains rhBMP-2 in active form on its surface.

The work helped to develop a biomaterial in the shape of a film that has a high capacity for cell adhesion and is also able to retain on its surface the rhBMP-2 in active form.
Rendering of the three-dimensional structure of bone morphogenetic protein rhBMP-2.
Three-dimensional structure of rhBMP-2

What backs the research.

2004

University spin-off

Noricum is founded out of the Tissue Engineering and Bone Regeneration Group at the Complutense University of Madrid.

BMP

In-house protein production

In-house protocols for cloning, expression, folding and purification, with no organic solvents or detergents in the folding step.

PCT

International patent

Spanish patent PE20002057, filed as PCT/ES01/00322. It passed the State of the Matter examination by the European Patent Office, which recognised the inventive activity.

2011

Own facilities

Registered as a manufacturer and marketer of medical devices with the Ministry of Health, with facilities to produce the recombinant protein and to coat implants and 3D matrices.

The biomaterial

A carrier that releases the protein.

Scanning electron microscopy of the regeneration material: the porous structure is what allows cells to colonise the graft and the protein to stay retained on the surface.

  • Increasing the speed of osseointegration of dental implants in the host bone, and the quality of the bone-implant interface.
  • Developing new multifunctional biomaterials for bone augmentation and regeneration.
Scanning electron microscopy of the bone regeneration biomaterial, at 1 mm and 100 µm scales.

Research lines

Two lines, one goal.

L1rhBMP-2

Recombinant bone morphogenetic protein 2

Production of recombinant human bone morphogenetic protein 2 at the company's own facilities.

L2Iso-bone® · Proteo-Graft™

Bone regeneration materials

Two products, one derived from the other.

  • Iso-bone®

    Bovine bone mineral for bone regeneration.

  • Proteo-Graft™

    A combination product: a bovine bone mineral matrix loaded with rhBMP-2.

Comparative tibia radiograph: control on the left, rhBMP-2 coated implant on the right.

What was measured

Experiment in a rabbit tibia to test the increase in bone height with implants coated with the rhBMP-2 film. In the image, control on the left and test on the right.

A 3 mm increase in bone height

Preclinical result in an animal model. It does not constitute a clinical indication.

Installed capacity

We do not only manufacture our own.

  • S-01

    rhBMP-2 for research

    Production and distribution of bone morphogenetic protein 2 for research use, at an affordable cost because it is manufactured in our own facilities.

  • S-02

    ISO 7 clean rooms

    Clean rooms available for other companies to outsource trials and processes.